Skin innate immune system in psoriasis: friend or foe? - PubMed (original) (raw)
Review
. 1999 Nov;104(9):1161-4.
doi: 10.1172/JCI8633.
Affiliations
- PMID: 10545511
- PMCID: PMC409832
- DOI: 10.1172/JCI8633
Review
Skin innate immune system in psoriasis: friend or foe?
B J Nickoloff. J Clin Invest. 1999 Nov.
No abstract available
Figures
Figure 1
Clinical photograph of extensive psoriatic plaque formation with protective shield-like appearance encircling the trunk, arms, and lower back/buttocks.
Figure 2
Schematic representation depicting how a confederacy of innate immunity-based genes and cells may conspire to create a psoriatic lesion. Whether triggered by an exogenous event that disrupts KC barrier function (with or without bacterial infection) or by an endogenously-derived infiltration of activated immunocytes, the final mature psoriatic plaque includes an epidermal compartment resistant to infections, apoptosis, and transformation. The complexity of interactions between innate immunity and acquired immunity in skin is depicted as a multi-step model highlighting 2 key abnormalities in psoriasis, including (a) defective terminal differentiation/barrier function and (b) hyperreactivity of the skin immune system including T cells bearing NKRs, which can evolve into a full-fledged Th1-type cell-mediated reaction involving adaptive immune components.
Figure 3
Potential means to reverse the hyperresponsiveness of psoriatic skin. Possible intervention points based on a multistep model of psoriasis, beginning with inflammatory-type reactions involving innate immunity and culminating in acquired immunity and activation of an angiogenic switch.
Comment on
- Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis.
Travers JB, Hamid QA, Norris DA, Kuhn C, Giorno RC, Schlievert PM, Farmer ER, Leung DY. Travers JB, et al. J Clin Invest. 1999 Nov;104(9):1181-9. doi: 10.1172/JCI6835. J Clin Invest. 1999. PMID: 10545517 Free PMC article. Clinical Trial.
Similar articles
- Natural killer cells in psoriasis.
Tobin AM, Lynch L, Kirby B, O'Farrelly C. Tobin AM, et al. J Innate Immun. 2011;3(4):403-10. doi: 10.1159/000328011. Epub 2011 May 25. J Innate Immun. 2011. PMID: 21613780 Review. - Psoriasis: dysregulation of innate immunity.
Bos JD, de Rie MA, Teunissen MB, Piskin G. Bos JD, et al. Br J Dermatol. 2005 Jun;152(6):1098-107. doi: 10.1111/j.1365-2133.2005.06645.x. Br J Dermatol. 2005. PMID: 15948970 Review. - Immunopathogenesis of psoriasis: focus on natural killer T cells.
Peternel S, Kastelan M. Peternel S, et al. J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1123-7. doi: 10.1111/j.1468-3083.2009.03292.x. Epub 2009 Apr 30. J Eur Acad Dermatol Venereol. 2009. PMID: 19453772 Review. - Animal models of psoriasis: a critical appraisal.
Schön MP. Schön MP. Exp Dermatol. 2008 Aug;17(8):703-12. doi: 10.1111/j.1600-0625.2008.00751.x. Epub 2008 Jun 28. Exp Dermatol. 2008. PMID: 18557923 Review. - Immunopathogenesis of psoriasis.
Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K, Volk HD, Sterry W, Wolk K. Sabat R, et al. Exp Dermatol. 2007 Oct;16(10):779-98. doi: 10.1111/j.1600-0625.2007.00629.x. Exp Dermatol. 2007. PMID: 17845210 Review.
Cited by
- Cutaneous microdialysis: cytokine evidence for altered innate reactivity in the skin of psoriasis patients?
Sjögren F, Davidsson K, Sjöström M, Anderson CD. Sjögren F, et al. AAPS J. 2012 Jun;14(2):187-95. doi: 10.1208/s12248-012-9331-z. Epub 2012 Feb 29. AAPS J. 2012. PMID: 22374383 Free PMC article. - Innate immunity and antimicrobial defense systems in psoriasis.
Büchau AS, Gallo RL. Büchau AS, et al. Clin Dermatol. 2007 Nov-Dec;25(6):616-24. doi: 10.1016/j.clindermatol.2007.08.016. Clin Dermatol. 2007. PMID: 18021900 Free PMC article. Review. - Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences.
Boehncke WH. Boehncke WH. Front Immunol. 2018 Apr 5;9:579. doi: 10.3389/fimmu.2018.00579. eCollection 2018. Front Immunol. 2018. PMID: 29675020 Free PMC article. Review. - Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions.
Tauchi M, Hida A, Negishi T, Katsuoka F, Noda S, Mimura J, Hosoya T, Yanaka A, Aburatani H, Fujii-Kuriyama Y, Motohashi H, Yamamoto M. Tauchi M, et al. Mol Cell Biol. 2005 Nov;25(21):9360-8. doi: 10.1128/MCB.25.21.9360-9368.2005. Mol Cell Biol. 2005. PMID: 16227587 Free PMC article. - Immunopathogenesis of psoriasis.
Nickoloff BJ, Qin JZ, Nestle FO. Nickoloff BJ, et al. Clin Rev Allergy Immunol. 2007 Oct;33(1-2):45-56. doi: 10.1007/s12016-007-0039-2. Clin Rev Allergy Immunol. 2007. PMID: 18094946 Review.
References
- Farber EM, Nall LM. The natural history of psoriasis in 5600 patients. Dermatologica. 1974;148:1–18. - PubMed
- Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell. 1996;85:311–318. - PubMed
- Elias, P.M., et al. 1993. Normal mechanisms and pathophysiology of epidermal permeability barrier homeostasis. Curr. Opin. Dermatol. 231–237.
- Tsai J-C, et al. Permeability barrier disruption alters the localization and expression of TNF-alpha protein in the epidermis. Arch Dermatol Res. 1996;286:242–248. - PubMed